









Markets
/
Stocks
/
nasdaq-armp
/

Armata Pharmaceuticals Inc

ARMP

7.700USD

-0.380-4.70%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

278.97MMarket Cap

LossP/E TTM



Armata Pharmaceuticals Inc

7.700

-0.380-4.70%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Armata Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Armata Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 131 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Armata Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

131 / 392

Overall Ranking

269 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Armata Pharmaceuticals Inc Highlights

StrengthsRisks

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.17M.

Undervalued

The company’s latest PE is -5.94, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 41.30K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

12.000

Target Price

+48.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Armata Pharmaceuticals Inc is 5.41, ranking 369 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.16M, representing a year-over-year decrease of 61.02%, while its net profit experienced a year-over-year decrease of 386.68%.

Score

Industry at a Glance

Previous score

5.41

Change



Financials

4.09

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.86

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Armata Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Armata Pharmaceuticals Inc is 6.45, ranking 277 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.94, which is -100.00% below the recent high of 0.00 and -3531.16% above the recent low of -215.85.

Score

Industry at a Glance

Previous score

6.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Armata Pharmaceuticals Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 9.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

12.000

Target Price

+48.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Armata Pharmaceuticals Inc

ARMP

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Armata Pharmaceuticals Inc is 9.41, ranking 12 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.73 and the support level at 6.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.71

Change

-0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.340

Buy

RSI(14)

60.674

Neutral

STOCH(KDJ)(9,3,3)

84.815

Neutral

ATR(14)

0.587

Low Volatility

CCI(14)

104.503

Buy

Williams %R

20.968

Buy

TRIX(12,20)

0.723

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

7.874

Sell

MA10

7.188

Buy

MA20

6.726

Buy

MA50

6.435

Buy

MA100

5.516

Buy

MA200

3.834

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Armata Pharmaceuticals Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.17%, representing a quarter-over-quarter decrease of 1.92%. The largest institutional shareholder is The Vanguard, holding a total of 357.65K shares, representing 0.98% of shares outstanding, with 36.67% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Innoviva Inc

25.08M

The Vanguard Group, Inc.

Star Investors

297.04K

+14.21%

Geode Capital Management, L.L.C.

104.55K

Edgewood Management LLC

100.00K

Pastagia (Mina M.D.)

61.08K

Bridgeway Capital Management, LLC

44.68K

Renaissance Technologies LLC

Star Investors

41.30K

+6.17%

Seacrest Wealth Management, LLC

34.95K

State Street Investment Management (US)

40.30K

GSB Wealth Management, LLC

30.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Armata Pharmaceuticals Inc is 1.24, ranking 337 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.